Hamlet BioPharma AB (publ)

NGM:HAMLET B Stock Report

Market Cap: SEK 439.5m

Hamlet BioPharma Valuation

Is HAMLET B undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Book vs Peers

  • Price-To-Book vs Industry

  • Price-To-Book vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of HAMLET B when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate HAMLET B's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate HAMLET B's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for HAMLET B?

Key metric: As HAMLET B is unprofitable and pre-revenue we use its Price-To-Book Ratio for relative valuation analysis.

The above table shows the Price to Book ratio for HAMLET B. This is calculated by dividing HAMLET B's market cap by their current book value.
What is HAMLET B's PB Ratio?
PB Ratio8.1x
BookSEK 54.19m
Market CapSEK 439.54m

Price to Book Ratio vs Peers

How does HAMLET B's PB Ratio compare to its peers?

The above table shows the PB ratio for HAMLET B vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PBEstimated GrowthMarket Cap
Peer Average4.8x
ISOFOL Isofol Medical
5.2xn/aSEK 474.9m
FLUO FluoGuide
8.2x49.9%SEK 466.1m
ONCO Oncopeptides
2.4x35.8%SEK 330.5m
ABLI Abliva
3.2x-17.6%SEK 214.4m
HAMLET B Hamlet BioPharma
8.1xn/aSEK 439.5m

Price-To-Book vs Peers: HAMLET B is expensive based on its Price-To-Book Ratio (8.1x) compared to the peer average (4.8x).

Price to Book Ratio vs Industry

How does HAMLET B's PB Ratio compare vs other companies in the SE Biotechs Industry?

8 CompaniesPrice / BookEstimated GrowthMarket Cap
COMBI CombiGene
0.6xn/aUS$4.59m
EXPRS2 ExpreS2ion Biotech Holding
0.6x-11.9%US$3.66m
SCOL Scandion Oncology
0.5x69.7%US$1.52m
DIABIO Diagonal Bio
0.5xn/aUS$1.23m
HAMLET B 8.1xIndustry Avg. 2.4xNo. of Companies11PB02.44.87.29.612+
8 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Book vs Industry: HAMLET B is expensive based on its Price-To-Book Ratio (8.1x) compared to the Swedish Biotechs industry average (2.4x).

Price to Book Ratio vs Fair Ratio

What is HAMLET B's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

HAMLET B PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio8.1x
Fair PB Ration/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate HAMLET B's Price-To-Book Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

AstraZeneca

UK£162.4b

A biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines.

AZN

UK£1,462.00

7D

5.0%

1Y

8.2%

Swedish Orphan Biovitrum

SEK 99.6b

An integrated biotechnology company, researches, develops, manufactures, and sells pharmaceuticals in the therapeutic areas of haematology, immunology, and specialty care in Europe, North America, the Middle East, Asia, and Australia.

SOBI

SEK 290.00

7D

-2.7%

1Y

14.5%

PMD Device Solutions

SEK 35.3m

A digital medical device company, develops and sells respiratory monitoring solutions in Ireland.

PMDS

SEK 1.36

7D

-8.1%

1Y

n/a